- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04314739
The Effects of Resveratrol Supplementation on Inflammation and Cognitive Performance in Healthy Adults
The Acute and Chronic Effects of Resveratrol Supplementation on Inflammation and Cognitive Performance in Healthy Adults
Previous research has suggested that high levels of systemic inflammation can contribute to cognitive deficits and additional health problems; consumption of polyphenols have been shown to have an anti-inflammatory effect. Resveratrol, a polyphenol found primarily in red grape skins, has previously been shown to improve brain blood flow and possibly brain function and may potentially reduce systemic inflammation, however there is limited research into this.
This study will investigate the effects of 4 weeks daily consumption of resveratrol on inflammation and cognitive function in healthy adults.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Each participant will be required to attend the laboratory on three occasions. The first of these will be an initial screening/training visit, this will take place in the afternoon and last 2 1/2 hours in total. During the initial visit participants will be asked to provide written informed consent. They will provide lifestyle and demographic data and screened regards to physical health (height, weight, blood pressure, waist to hip ratio). They will then complete a food frequency questionnaire and be trained on the computerised cognitive and mood tasks. Participants will also be trained on completing the cognitive assessment battery on their mobile phone, they will complete a further 5 assessments on their phone, once the day before their first visit and every 7 days during the supplementation period.
Study days 1 and 2 (4 weeks apart) :
Participants will arrive at the laboratory at an agreed time in the morning (7am, 8.30am or 10am) having fasted for 12 hours, avoided caffeinated products for 18 hours, alcohol and over the counter medication for 24 hours and oral antihistamines for 48 hours prior to the session commencing.
Participants will provide a blood sample, they will then complete a short computerised cognitive assessment (~20 minutes in length), followed by measurements of blood pressure and heart rate. Following this the participants will consume their treatment for the day, followed by a 40 minute absorption period and then will complete the second cognitive assessment. Participants will then provide a second blood sample. At the end of the first study session participants will be provided with their treatment and treatment diary, they will be instructed to take one tablet twice a day (30 minutes after breakfast and dinner). Both study visits will be identical and will take place 29 days (+/- 2 days) apart.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tyne And Wear
-
Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 8ST
- Northumbria University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must self-assess themselves as being in good health.
- Aged 18 to 55 at the time of giving consent
Exclusion Criteria:
- Have a Body Mass Index (BMI) outside the range of 18.5-42kg/m2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Resveratrol
500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
|
Participants will consume one of the treatment types daily for a period of four weeks.
Other Names:
|
Placebo Comparator: Placebo
Matched placebo capsules (1 capsule consumed at two timepoints each day).
|
Participants will consume one of the treatment types daily for a period of four weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline concentration of biomarkers of systemic inflammation
Time Frame: 1 hour post dose; 4 weeks
|
Assessment of change from baseline: C reactive protein, tumor necrosis factor alpha and interleukin 6.
|
1 hour post dose; 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute changes in cognitive task performance
Time Frame: 40 minutes post dose
|
This will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program).
Changes in episodic memory, working memory, spatial memory, executive function and attention as compared to pre-treatment performance on day 1.
All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains.
|
40 minutes post dose
|
Interim changes in cognitive task performance
Time Frame: Day 7; Day 14; Day 21; Day 28
|
This will be assessed using a computerised cognitive battery, this will be administered using 'Cognimapp'mobile phone program, participants will complete this battery away from home using their own mobile phone.
Changes in attention, executive function, working memory and episodic memory as compared to performance on Day -1.
All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains.
|
Day 7; Day 14; Day 21; Day 28
|
Chronic changes in cognitive task performance
Time Frame: 4 weeks
|
This will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program).
Changes in episodic memory, working memory, spatial memory, executive function and attention as compared to pre-treatment performance on day 1.
All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains.
|
4 weeks
|
Acute changes in mood
Time Frame: 40 mins post dose
|
Assessed using Visual Analogue Mood Scales at each assessment during each cognitive assessment.
Participants will complete 27 separate visual analogue mood scales that load onto 3 mood outcomes: Alertness, Stress and Tranquillity (the individual scale results are averaged to create this score).
A score between 0 and 100 can be obtained, where a higher value indicates that the participant felt more Alert, Stressed or Tranquil.
|
40 mins post dose
|
Interim changes in mood
Time Frame: Day 7; Day 14; Day 21; Day 28
|
Assessed using Visual Analogue Mood Scales at each assessment during the interim supplementation period.
Participants will complete 27 separate visual analogue mood scales that load onto 3 mood outcomes: Alertness, Stress and Tranquillity (the individual scale results are averaged to create this score).
A score between 0 and 100 can be obtained, where a higher value indicates that the participant felt more Alert, Stressed or Tranquil.
|
Day 7; Day 14; Day 21; Day 28
|
Chronic changes in mood
Time Frame: 4 weeks
|
Assessed using the Profile of Mood States questionnaire, completed at the start of each testing visit.
The questionnaire includes 65 items and participants rate their mood on a scale of 0-4 (not at all - extremely).
These scores are collapsed into 6 mood outcomes (Tension, depression, anger, vigour, fatigue and confusion) and a total mood disturbance score.
|
4 weeks
|
Acute changes in concentration of plasma and serum biomarkers
Time Frame: 1 hour post dose
|
Biomarkers of insulin, glucose, cholesterol and resveratrol metabolites will be measured in plasma and serum using liquid chromatography-mass spectrometry and ELISA analysis in association with other endpoints.
|
1 hour post dose
|
Chronic changes in concentration of plasma and serum biomarkers
Time Frame: 4 weeks
|
Biomarkers of insulin, glucose, cholesterol and resveratrol metabolites will be measured in plasma and serum using liquid chromatography-mass spectrometry and ELISA analysis in association with other endpoints.
|
4 weeks
|
Acute and chronic changes in blood pressure
Time Frame: 1 hour post dose, 4 weeks
|
Systolic and diastolic blood pressure will be taken after each cognitive assessment (measured in mm Hg).
|
1 hour post dose, 4 weeks
|
Acute and chronic changes in heart rate
Time Frame: 1 hour post dose, 4 weeks
|
Heart rate will be measured after each cognitive assessment (measured in BPM).
|
1 hour post dose, 4 weeks
|
Changes in weight and Body Mass Index (BMI)
Time Frame: 4 weeks
|
Participants weight will be recorded at testing visits and BMI will be calculated.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Emma L Wightman, Dr, Northumbria University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 52P7
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Change
-
University Ramon LlullAinhoa Nieto Guisado; Mònica Solana-TramuntUnknownCognitive Change | Proprioception Change | Balance ChangeSpain
-
Applied Science & Performance InstituteRecruitingCognitive Change | Mood Change | Mental ProcessesUnited States
-
National Council of Scientific and Technical Research...CompletedSleep | Cognitive Change | Mood Change | CreativityArgentina
-
Wake Forest UniversityNot yet recruiting
-
Biruni UniversityCompletedCognitive ChangeTurkey
-
University of MemphisCalerie LLCCompletedCognitive ChangeUnited States
-
Oregon Health and Science UniversityCompleted
-
University of MiamiUnited States Department of DefenseCompleted
-
Northumbria UniversityPerfetti van Melle SPACompletedCognitive ChangeUnited Kingdom
-
Universidad de GranadaCompleted
Clinical Trials on Resveratrol
-
University at BuffaloKaleida HealthTerminatedObesity | Insulin Resistance | Type 2 DiabetesUnited States
-
Jupiter Orphan Therapeutics Inc.National Institute on Aging (NIA)CompletedPharmacokinetics | Food-drug Interaction | SafetyUnited States
-
MaineHealthAmerican Heart AssociationActive, not recruitingCoronary Artery Disease | Diabetes Mellitus, Type 2United States
-
Bernard FiorettiCompleted
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.Completed
-
Albert Einstein College of MedicineAmerican Diabetes AssociationCompletedImpaired Glucose ToleranceUnited States
-
Federal University of Rio Grande do SulCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Completed
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedCoronary Artery Disease | Blood Pressure | Heart Rate | Autonomic Nervous System DiseaseBrazil
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.; Diabetes FondsCompleted
-
University of FloridaCompleted